Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib continued access rollover study after prior Novartis remibrutinib trials
2025-524078-40-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of remibrutinib in chronic idiopathic urticaria (CIU), sponsored by Novartis. Primary endpoints: Serious adverse events and Adverse events. Planned start Jun 2026; status: authorised.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2025-524078-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524078-40-00.